Evolent Health (NYSE:EVH - Get Free Report) was upgraded by stock analysts at Truist Financial from a "hold" rating to a "buy" rating in a research note issued to investors on Friday, FinViz reports. The firm presently has a $6.00 price objective on the technology company's stock. Truist Financial's price target would indicate a potential upside of 75.18% from the stock's previous close.
A number of other brokerages have also issued reports on EVH. Needham & Company LLC raised their target price on Evolent Health from $5.00 to $6.00 and gave the stock a "buy" rating in a research note on Thursday, November 5th. TD Cowen lifted their price target on Evolent Health from $5.00 to $6.00 and gave the stock a "buy" rating in a research report on Monday, August 17th. JPMorgan Chase & Co. boosted their price target on Evolent Health from $5.00 to $6.00 and gave the company an "overweight" rating in a research note on Tuesday, August 18th. Weiss Ratings raised Evolent Health from a "sell (e+)" rating to a "sell (d-)" rating in a report on Monday, November 9th. Finally, Canaccord Genuity Group reduced their price objective on Evolent Health from $7.00 to $6.00 and set a "buy" rating for the company in a research note on Monday, August 10th. Eleven equities research analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Evolent Health has a consensus rating of "Moderate Buy" and a consensus price target of $6.04.
Get Our Latest Report on Evolent Health
Evolent Health Stock Down 12.8%
NYSE:EVH opened at $3.42 on Friday. The company has a market cap of $387.40 million, a PE ratio of -0.75 and a beta of 1.03. Evolent Health has a twelve month low of $2.10 and a twelve month high of $6.26. The company has a current ratio of 1.26, a quick ratio of 1.26 and a debt-to-equity ratio of 2.60. The company's 50 day moving average is $4.21 and its two-hundred day moving average is $3.93.
Evolent Health (NYSE:EVH - Get Free Report) last issued its quarterly earnings results on Thursday, November 5th. The technology company reported $0.06 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $0.06. Evolent Health had a negative net margin of 21.67% and a negative return on equity of 6.07%. The business had revenue of $725.37 million for the quarter, compared to analyst estimates of $727.06 million. During the same quarter in the prior year, the business posted $0.05 EPS. Evolent Health's revenue for the quarter was up 51.3% compared to the same quarter last year. Analysts anticipate that Evolent Health will post -0.25 EPS for the current year.
Insiders Place Their Bets
In other Evolent Health news, President Daniel Mccarthy sold 65,892 shares of the stock in a transaction dated Wednesday, August 26th. The stock was sold at an average price of $5.00, for a total transaction of $329,460.00. Following the sale, the president directly owned 655,133 shares of the company's stock, valued at approximately $3,275,665. This trade represents a 9.14% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 1.48% of the company's stock.
Institutional Inflows and Outflows
A number of large investors have recently bought and sold shares of the stock. HB Wealth Management LLC increased its holdings in shares of Evolent Health by 6.8% during the 2nd quarter. HB Wealth Management LLC now owns 35,842 shares of the technology company's stock valued at $194,000 after purchasing an additional 2,282 shares in the last quarter. WINTON GROUP Ltd grew its position in Evolent Health by 29.6% during the second quarter. WINTON GROUP Ltd now owns 26,700 shares of the technology company's stock valued at $145,000 after buying an additional 6,100 shares during the period. Wealthfront Advisers LLC grew its position in Evolent Health by 40.8% during the first quarter. Wealthfront Advisers LLC now owns 28,083 shares of the technology company's stock valued at $64,000 after buying an additional 8,136 shares during the period. Royal Bank of Canada grew its position in Evolent Health by 51.6% during the first quarter. Royal Bank of Canada now owns 25,161 shares of the technology company's stock valued at $57,000 after buying an additional 8,563 shares during the period. Finally, 49 Wealth Management LLC purchased a new position in Evolent Health in the third quarter valued at $36,000.
Evolent Health Company Profile
(
Get Free Report)
Evolent Health, Inc. provides technology-enabled services to health plans and healthcare providers in the United States. The company helps clients manage care, coordinate services and support the delivery of healthcare, particularly for people with complex medical needs. Its offerings include specialty care management programs, clinical and administrative services, and technology that supports care decisions and operations. Evolent has focused on areas such as oncology, cardiology, musculoskeletal care and behavioral health.
See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Evolent Health, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Evolent Health wasn't on the list.
While Evolent Health currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2026. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.
Get This Free Report
Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.
Like this article? Share it with a colleague.
Link copied to clipboard.